Find Novel Dermatology Drugs in Preclinical Development

Lead Product(s): WEG232

Therapeutic Area: Dermatology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 19, 2020

Details:

WEG232 topical treatment showed a 71% reduction in SD-Rats with erlotinib-induced facial rash/hair loss.

Lead Product(s): Antimicrobial therapy

Therapeutic Area: Dermatology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

The BioLexa Platform is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach treating atopic dermatitis.

Lead Product(s): Staphylococcus epidermidis strain

Therapeutic Area: Dermatology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skin care products under a future License Agreement.